

## DAFTAR PUSTAKA

- Aggarwal, B. B. *et al.* (2009) "Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?," *Annals of the New York Academy of Sciences*. Wiley, 1171(1), pp. 59–76. doi: 10.1111/j.1749-6632.2009.04911.x.
- Ahmad, U., Yusuf Alhaji, S. and Malami, S. A. (2020) "Genetic profiling and in vitro characterization of OTX1 functional role on bladder cancer stem cells." My University. doi: 10.60763/AFRICARXIV/748.
- Al-Gallab, M. I., Naddaf, L. A. and Kanan, M. R. (2009) "The management of non-invasive bladder tumours with Doxorubicin intravesical instillation after transurethral resection," *Sultan Qaboos University medical journal*, 9(1), pp. 53–58. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21509275>.
- An, X. *et al.* (2018) "The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer," *BMC cancer*. Springer Science and Business Media LLC, 18(1). doi: 10.1186/s12885-018-4170-7.
- Anastasiadis, A. and de Reijke, T. M. (2012) "Best practice in the treatment of nonmuscle invasive bladder cancer," *Therapeutic advances in urology*. SAGE Publications, 4(1), pp. 13–32. doi: 10.1177/1756287211431976.
- Babjuk, M. *et al.* (2019) "European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update," *European urology*. Elsevier BV, 76(5), pp. 639–657. doi: 10.1016/j.eururo.2019.08.016.
- Babjuk, M. *et al.* (2022) "European association of urology guidelines on non-muscle-invasive bladder cancer (ta, T1, and carcinoma in situ)," *European urology*. Elsevier BV, 81(1), pp. 75–94. doi: 10.1016/j.eururo.2021.08.010.
- Bai, Y. *et al.* (2016) "Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer," *Journal of ovarian research*. Springer Science and Business Media LLC, 9(1). doi: 10.1186/s13048-016-0244-9.
- Beukers, W. *et al.* (2013) "Hypermethylation of the polycomb group target gene *PCDH7* in bladder tumors from patients of all ages," *The journal of urology*.

Ovid Technologies (Wolters Kluwer Health), 190(1), pp. 311–316. doi: 10.1016/j.juro.2013.01.078.

Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. (2001) "*Clinical pharmacology and therapeutics*," Wiley, 69(3), pp. 89–95. doi: 10.1067/mcp.2001.113989.

*Cancer facts & figures* (2020). Available at: <https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2020.html> (Accessed: July 8, 2024).

Cappellen, D. *et al.* (1999) "Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas," *Nature genetics*. Springer Science and Business Media LLC, 23(1), pp. 18–20. doi: 10.1038/12615.

Cassell, A. *et al.* (2019) "Non-muscle invasive bladder cancer: A review of the current trend in Africa," *World journal of oncology*. Elmer Press, Inc., 10(3), pp. 123–131. doi: 10.14740/wjon1210.

Cavaliere *et al.* (2014). "Non Muscle Invasive Bladder Cancer Treatment" WCRJ. Available at: <https://www.wcrj.net/article/126> (Accessed: July 8, 2024).

Chan, J. Y.-L. *et al.* (2022) "Mitigating the multicollinearity problem and its machine learning approach: A review," *Mathematics*. MDPI AG, 10(8), p. 1283. doi: 10.3390/math10081283.

Chan, S. *et al.* (2011) "Use of topoisomerase II alpha (TOP2A) protein overexpression to predict response to anthracycline-based chemotherapy," *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. American Society of Clinical Oncology (ASCO), 29(15\_suppl), pp. 1027–1027. doi: 10.1200/jco.2011.29.15\_suppl.1027.

Chang, S. S. *et al.* (2016) "Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline," *The journal of urology*. Ovid Technologies (Wolters Kluwer Health), 196(4), pp. 1021–1029. doi: 10.1016/j.juro.2016.06.049.

Chen, C. *et al.* (2018) "Autophagy and doxorubicin resistance in cancer," *Anti-cancer drugs*. Ovid Technologies (Wolters Kluwer Health), 29(1), pp. 1–9. doi: 10.1097/cad.0000000000000572.

- Chen, S. *et al.* (2019) “Establishing the prediction models for recurrence and progression of T1G3 bladder urothelial carcinoma,” *Journal of cancer*. Ivyspring International Publisher, 10(24), pp. 5891–5902. doi: 10.7150/jca.35866.
- Chen, T. *et al.* (2015) “Topoisomerase II $\alpha$  in chromosome instability and personalized cancer therapy,” *Oncogene*. Springer Science and Business Media LLC, 34(31), pp. 4019–4031. doi: 10.1038/onc.2014.332.
- Cheng, C. W. *et al.* (2005) “17-year follow-up of a randomized prospective controlled trial of adjuvant intravesical doxorubicin in the treatment of superficial bladder cancer,” *International braz j urol: official journal of the Brazilian Society of Urology*. FapUNIFESP (SciELO), 31(3), pp. 204–213. doi: 10.1590/s1677-55382005000300003.
- Chien, A. J. and Moasser, M. M. (2008) “Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired,” *Seminars in oncology*. Elsevier BV, 35(2 Suppl 2), pp. S1–S14; quiz S39. doi: 10.1053/j.seminoncol.2008.02.010.
- Christensen, E. *et al.* (2017) “Liquid biopsy analysis of FGFR3 and PIK3CA hotspot mutations for disease surveillance in bladder cancer,” *European urology*. Elsevier BV, 71(6), pp. 961–969. doi: 10.1016/j.eururo.2016.12.016.
- Cox, J. and Weinman, S. (2016) “Mechanisms of doxorubicin resistance in hepatocellular carcinoma,” *Hepatic oncology*. Informa UK Limited, 3(1), pp. 57–59. doi: 10.2217/hep.15.41.
- Cui, Z. *et al.* (2020) “Long non-coding RNA LINC00346 contributes to cisplatin resistance in nasopharyngeal carcinoma by repressing miR-342-5p,” *Open biology*. The Royal Society, 10(5). doi: 10.1098/rsob.190286.
- Dai, S. *et al.* (2019) “Fibroblast growth factor receptors (FGFRs): Structures and small molecule inhibitors,” *Cells (Basel, Switzerland)*. MDPI AG, 8(6), p. 614. doi: 10.3390/cells8060614.

- Daoud, J. I. (2017) "Multicollinearity and Regression Analysis," *Journal of physics. Conference series*. IOP Publishing, 949, p. 012009. doi: 10.1088/1742-6596/949/1/012009.
- Demir, S. *et al.* (2019) "TWIST1 Gene expression as a biomarker for predicting primary doxorubicin resistance in breast cancer," *Balkan journal of medical genetics: BJMG*. Walter de Gruyter GmbH, 22(2), pp. 25–30. doi: 10.2478/bjmg-2019-0025.
- Denard, B. *et al.* (2018) "CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy," *BMC cancer*. Springer Science and Business Media LLC, 18(1). doi: 10.1186/s12885-018-4724-8.
- Depowski, P. L. *et al.* (2000) "Topoisomerase II $\alpha$  expression in breast cancer: Correlation with outcome variables," *Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc.* Elsevier BV, 13(5), pp. 542–547. doi: 10.1038/modpathol.3880094.
- Di, C. *et al.* (2005) "Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid," *Cancer research*, 65(3), pp. 919–924. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15705891>.
- Donehower, L. A. *et al.* (2019) "Integrated analysis of TP53 gene and pathway alterations in The Cancer Genome Atlas," *Cell reports*. Elsevier BV, 28(5), pp. 1370-1384.e5. doi: 10.1016/j.celrep.2019.07.001.
- Fukuokaya, W. *et al.* (2020) "Effectiveness of intravesical doxorubicin immediately following resection of primary non-muscle-invasive bladder cancer: A propensity score-matched analysis," *Clinical genitourinary cancer*. Elsevier BV, 18(2), pp. e55–e61. doi: 10.1016/j.clgc.2019.09.005.
- Garg M. and Maurya N. (2019). WNT/ $\beta$ -catenin signaling in urothelial carcinoma of bladder. *World J Nephrol*. 8(5):83-94. doi: 10.5527/wjn.v8.i5.83. PMID: 31624709; PMCID: PMC6794554.
- Gibson, N. M. *et al.* (2013) "Doxorubicin-induced vascular dysfunction and its attenuation by exercise preconditioning," *Journal of cardiovascular*

*pharmacology*. Ovid Technologies (Wolters Kluwer Health), 62(4), pp. 355–360. doi: 10.1097/FJC.0b013e31829c9993.

Goldberg, I. P. *et al.* (2022) “Pharmacologic therapies for non-muscle invasive bladder cancer: Current and future treatments,” *Archives of pharmacology and therapeutics*. NIH Public Access, 4(1), pp. 13–22. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431226/> (Accessed: August 9, 2024).

Gou, L. *et al.* (2018) “BMP9 promotes the proliferation and migration of bladder cancer cells through up-regulating lncRNA UCA1,” *International journal of molecular sciences*. MDPI AG, 19(4), p. 1116. doi: 10.3390/ijms19041116.

de Haas, T. *et al.* (2006) “OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomas,” *Journal of neuropathology and experimental neurology*. Oxford University Press (OUP), 65(2), pp. 176–186. doi: 10.1097/01.jnen.0000199576.70923.8a.

He, Y. *et al.* (2022) “Enhanced anti-glioma efficacy of doxorubicin with BRD4 PROTAC degrader using targeted nanoparticles,” *Materials today. Bio*. Elsevier BV, 16(100423), p. 100423. doi: 10.1016/j.mtbio.2022.100423.

Hong, H.-H. *et al.* (2016) “Long non-coding RNA *UCA1* is a predictive biomarker of cancer,” *Oncotarget*. Impact Journals, LLC, 7(28), pp. 44442–44447. doi: 10.18632/oncotarget.10142.

Ifeanyi, O. E. (2018) “A review on bladder tumor antigens,” *Cancer therapy & oncology international journal*. Juniper Publishers, 9(3). doi: 10.19080/ctoj.2018.09.555762.

Isaacs, R. J. *et al.* (1998) “Physiological regulation of eukaryotic topoisomerase II,” *Biochimica et Biophysica Acta - Gene Structure and Expression*. Elsevier BV, 1400(1–3), pp. 121–137. doi: 10.1016/s0167-4781(98)00131-6.

Jain, M. *et al.* (2013) “TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma,” *Endocrine-related cancer*. Bioscientifica, 20(3), pp. 361–370. doi: 10.1530/erc-12-0403.

- Jiang, L. *et al.* (2021) “Orthodenticle homeobox OTX1 is a potential prognostic biomarker for bladder cancer,” *Bioengineered*. Informa UK Limited, 12(1), pp. 6559–6571. doi: 10.1080/21655979.2021.1974646.
- Jiang, S.-J., Ye, L.-Y. and Meng, F.-H. (2016) “Comparison of intravesical bacillus Calmette-Guerin and mitomycin C administration for non-muscle invasive bladder cancer: A meta-analysis and systematic review,” *Oncology letters*. Spandidos Publications, 11(4), pp. 2751–2756. doi: 10.3892/ol.2016.4325.
- Jiang, Y.-H. *et al.* (2024) “Hypermethylation loci of ZNF671, IRF8, and OTX1 as potential urine-based predictive biomarkers for bladder cancer,” *Diagnostics (Basel, Switzerland)*. MDPI AG, 14(5), p. 468. doi: 10.3390/diagnostics14050468.
- Kacew, A. and Sweis, R. F. (2020) “FGFR3 alterations in the era of immunotherapy for urothelial bladder cancer,” *Frontiers in immunology*. Frontiers Media SA, 11. doi: 10.3389/fimmu.2020.575258.
- Kamat, A. M., Bagcioglu, M. and Huri, E. (2017) “What is new in non-muscle-invasive bladder cancer in 2016?,” *Turkish journal of urology*. AVES YAYINCILIK A.Ş., 43(1), pp. 9–13. doi: 10.5152/tud.2017.60376.
- Kandimalla, R. *et al.* (2013) “A 3-plex methylation assay combined with the *FGFR3* mutation assay sensitively detects recurrent bladder cancer in voided urine,” *Clinical cancer research: an official journal of the American Association for Cancer Research*. American Association for Cancer Research (AACR), 19(17), pp. 4760–4769. doi: 10.1158/1078-0432.ccr-12-3276.
- Kassouf, W. *et al.* (2015) “CUA guidelines on the management of non-muscle invasive bladder cancer,” *Journal de l'Association des urologues du Canada [Canadian Urological Association journal]*. Canadian Urological Association Journal, 9(9–10), p. 690. doi: 10.5489/cuaj.3320.
- Katoh M. *et al.* (2024). FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions. *Nat Rev Clin Oncol*. 2024 Apr;21(4):312-329. doi: 10.1038/s41571-024-00869-z. Epub 2024 Feb 29. PMID: 38424198.

- Kciuk, M. *et al.* (2023) “Doxorubicin—an agent with multiple mechanisms of anticancer activity,” *Cells (Basel, Switzerland)*. MDPI AG, 12(4), p. 659. doi: 10.3390/cells12040659.
- Kikuchi, A. *et al.* (2017) “ASP5878, a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance,” *Cancer science*. Wiley, 108(2), pp. 236–242. doi: 10.1111/cas.13124.
- Kim, B. N. *et al.* (2020) “TGF- $\beta$  induced EMT and stemness characteristics are associated with epigenetic regulation in lung cancer,” *Scientific reports*. Springer Science and Business Media LLC, 10(1), p. 10597. doi: 10.1038/s41598-020-67325-7.
- Kim, E.-J. *et al.* (2010) “Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non–muscle-invasive bladder cancer,” *Urology*. Elsevier BV, 75(6), p. 1516.e9-1516.e13. doi: 10.1016/j.urology.2009.08.055.
- Kim, J. H. (2019) “Multicollinearity and misleading statistical results,” *Korean journal of anesthesiology*. The Korean Society of Anesthesiologists, 72(6), pp. 558–569. doi: 10.4097/kja.19087.
- Kirk, J. S. *et al.* (2015) “Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer,” *Oncotarget*. Impact Journals, LLC, 6(5), pp. 3136–3146. doi: 10.18632/oncotarget.3077.
- Kirkali, Z. and Canda, A. E. (2006) “Superficial urothelial cancer in the prostatic urethra,” *TheScientificWorldJournal*. Hindawi Limited, 6, pp. 2603–2610. doi: 10.1100/tsw.2006.402.
- Klein, W. H. and Li, X. (1999) “Function and evolution of otx proteins,” *Biochemical and biophysical research communications*. Elsevier BV, 258(2), pp. 229–233. doi: 10.1006/bbrc.1999.0449.
- Koren, R. *et al.* (2003) “Human DNA topoisomerase-IIalpha expression as a prognostic factor for transitional cell carcinoma of the urinary bladder,” *BJU international*, 91(6), pp. 489–492. doi: 10.1046/j.1464-410x.2003.04118.x.

- Krüger, S. *et al.* (2005) "Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder--a multitissue array study with prognostic implications," *Anticancer research*, 25(1A), pp. 263–271. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15816547>.
- Krzyszczuk, P. *et al.* (2018) "The growing role of precision and personalized medicine for cancer treatment," *Technology*. World Scientific Pub Co Pte Ltd, 6(3–4), pp. 79–100. doi: 10.1142/S2339547818300020.
- Lei, T. *et al.* (2019) "STAT3 signaling pathway in drug-resistant bladder cancer cell line," *Journal of biological regulators and homeostatic agents*, 33(5), pp. 1347–1357. doi: 10.23812/19-68-A.
- Levantini, E. *et al.* (2003) "Unsuspected role of the brain morphogenetic gene *Otx1* in hematopoiesis," *Proceedings of the National Academy of Sciences of the United States of America*. Proceedings of the National Academy of Sciences, 100(18), pp. 10299–10303. doi: 10.1073/pnas.1734071100.
- Li, H. *et al.* (2016) "OTX1 contributes to hepatocellular carcinoma progression by regulation of ERK/MAPK pathway," *Journal of Korean medical science*. Korean Academy of Medical Sciences, 31(8), p. 1215. doi: 10.3346/jkms.2016.31.8.1215.
- Liao, H. *et al.* (2015) "Suppression of cellular proliferation and invasion by HMGB1 knockdown in bladder urothelial carcinoma cells," *Oncology research*. Computers, Materials and Continua (Tech Science Press), 22(5), pp. 235–245. doi: 10.3727/096504015x14267282610858.
- Lidagoster, S. *et al.* (2024) "BCG and alternative therapies to BCG therapy for non-muscle-invasive bladder cancer," *Current oncology (Toronto, Ont.)*. MDPI AG, 31(2), pp. 1063–1078. doi: 10.3390/currenco131020079.
- Lindgren, D. *et al.* (2006) "Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q," *Oncogene*. Springer Science and Business Media LLC, 25(18), pp. 2685–2696. doi: 10.1038/sj.onc.1209249.

- Liu X. *et al.* (2014). Clinical significance of fibroblast growth factor receptor-3 mutations in bladder cancer: a systematic review and meta-analysis. *Genet Mol Res.* 2014 Feb 20;13(1):1109-20. doi: 10.4238/2014.February.20.12. PMID: 24634132.
- Liu, S.-B. *et al.* (2019) “Zebrafish FGFR3 is a negative regulator of RLR pathway to decrease IFN expression,” *Fish & shellfish immunology*. Elsevier BV, 92, pp. 224–229. doi: 10.1016/j.fsi.2019.06.002.
- Liu, Z. *et al.* (2021) “Regulatory role of long non-coding RNA UCA1 in signaling pathways and its clinical applications,” *Oncology letters*. Spandidos Publications, 21(5), p. 404. doi: 10.3892/ol.2021.12665.
- Liu, Z. *et al.* (2022) “Association between TOP2A, RRM1, HER2, ERCC1 expression and response to chemotherapy in patients with non-muscle invasive bladder cancer,” *Heliyon*. Elsevier BV, 8(6), p. e09643. doi: 10.1016/j.heliyon.2022.e09643.
- Lu, J. *et al.* (2022) “New Insights into LINC00346 and its Role in Disease,” *Frontiers in cell and developmental biology*. Frontiers Media SA, 9. doi: 10.3389/fcell.2021.819785.
- Liu, T. *et al.* (2022). BRD4 promotes the migration and invasion of bladder cancer cells through the Sonic hedgehog signaling pathway and enhances cisplatin resistance. *Biochemistry and Cell Biology*, 100(2), pp.179-187.
- Liu, Y. *et al.* (2020). Ligustrazine reverts anthracycline chemotherapy resistance of human breast cancer by inhibiting JAK2/STAT3 signaling and decreasing fibrinogen gamma chain (FGG) expression. *Am J Cancer Res.* 2020 Mar 1;10(3):939-952. PMID: 32266101; PMCID: PMC7136924.
- Lou, G *et al.* (2015). Differential distribution of U6 (RNU6-1) expression in human carcinoma tissues demonstrates the requirement for caution in the internal control gene selection for microRNA quantification. *Int J Mol Med.* 36(5):1400-8. doi: 10.3892/ijmm.2015.2338. Epub 2015 Sep 7. PMID: 26352225.
- Luo, H. *et al.* (2017) “MicroRNA-139-5p inhibits bladder cancer proliferation and self-renewal by targeting the Bmi1 oncogene,” *Tumour biology: the journal*

*of the International Society for Oncodevelopmental Biology and Medicine.*

SAGE Publications, 39(7), p. 1010428317718414. doi: 10.1177/1010428317718414.

Luo, J. *et al.* (2017) “LncRNA UCA1 promotes the invasion and EMT of bladder cancer cells by regulating the miR-143/HMGB1 pathway,” *Oncology letters*. Spandidos Publications. doi: 10.3892/ol.2017.6886.

Lu J. *et al.* (2022). New Insights into LINC00346 and its Role in Disease. *Front Cell Dev Biol.* 2022 Jan 13;9:819785. doi: 10.3389/fcell.2021.819785. PMID: 35096842; PMCID: PMC8794746.

Mano, M. S. *et al.* (2007) “The 17q12-q21 amplicon: Her2 and topoisomerase-II $\alpha$  and their importance to the biology of solid tumours,” *Cancer treatment reviews*. Elsevier BV, 33(1), pp. 64–77. doi: 10.1016/j.ctrv.2006.10.001.

Mao, W. *et al.* (2019) “Circular RNA hsa\_circ\_0068871 regulates FGFR3 expression and activates STAT3 by targeting miR-181a-5p to promote bladder cancer progression,” *Journal of experimental & clinical cancer research: CR*. Springer Science and Business Media LLC, 38(1), p. 169. doi: 10.1186/s13046-019-1136-9.

Marinello, J., Delcuratolo, M. and Capranico, G. (2018) “Anthracyclines as Topoisomerase II poisons: From early studies to new perspectives,” *International journal of molecular sciences*. MDPI AG, 19(11), p. 3480. doi: 10.3390/ijms19113480.

Meng, H. *et al.* (2019) “Selection and validation of reference genes for gene expression studies by RT-PCR in *Dalbergia odorifera*,” *Scientific reports*. Springer Science and Business Media LLC, 9(1). doi: 10.1038/s41598-019-39088-3.

Meredith, A.-M. and Dass, C. R. (2016) “Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism,” *The Journal of pharmacy and pharmacology*. Oxford University Press (OUP), 68(6), pp. 729–741. doi: 10.1111/jphp.12539.

Mirzaei, S. *et al.* (2021) “The involvement of epithelial-to-mesenchymal transition in doxorubicin resistance: Possible molecular targets,” *European journal of*

*pharmacology*. Elsevier BV, 908(174344), p. 174344. doi: 10.1016/j.ejphar.2021.174344.

Mohamedali, R. *et al.* (2023) "Expression of EZH2 and H3K27me3 predicts tumor biology of urothelial carcinoma," *Indian journal of pathology & microbiology*. Medknow, 66(3), pp. 488–494. doi: 10.4103/ijpm.ijpm\_1267\_21.

Nakopoulou, L. (2001) "Predictive value of topoisomerase IIalpha immunostaining in urothelial bladder carcinoma," *Journal of clinical pathology*. BMJ, 54(4), pp. 309–313. doi: 10.1136/jcp.54.4.309.

Niu, H. *et al.* (2022) "Depleted histone deacetylase 3 or restored microRNA-19b-1-5p facilitates recovery of spinal cord injury via inactivating JAK2/STAT3 signaling pathway," *Genomics*. Elsevier BV, 114(2), p. 110262. doi: 10.1016/j.ygeno.2021.12.019.

Nour, H. H. *et al.* (2015) "Low-dose bacille Calmette–Guérin for non-muscle-invasive bladder cancer: Results of a prospective study," *Arab journal of urology*. Informa UK Limited, 13(4), pp. 238–243. doi: 10.1016/j.aju.2015.09.005.

Omodei, D. *et al.* (2009) "Expression of the brain transcription factor OTX1 occurs in a subset of normal germinal-center B cells and in aggressive non-Hodgkin lymphoma," *The American journal of pathology*. Elsevier BV, 175(6), pp. 2609–2617. doi: 10.2353/ajpath.2009.090542.

Oosterlinck, W. *et al.* (2011) "Should all patients receive an immediate chemotherapeutic drug instillation after resection of papillary bladder tumors?," *European urology*. Elsevier BV, 59(3), pp. 374–376. doi: 10.1016/j.eururo.2010.12.002.

Pan, J. *et al.* (2016). "Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells". *Cancer letters*, 382(1), 64-76.

Pao, S.-I. *et al.* (2022) "MicroRNA-4516 suppresses proliferative vitreoretinopathy development via negatively regulating OTX1," *PloS one*. Public Library of Science (PLoS), 17(6), p. e0270526. doi: 10.1371/journal.pone.0270526.

- Parker, A. S. *et al.* (2014) “Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma,” *European urology*. Elsevier BV, 66(5), pp. 929–935. doi: 10.1016/j.eururo.2013.12.017.
- Pavone-Macaluso, M. *et al.* (1993) “Current views on intravesical treatment and chemoprophylaxis of superficial bladder cancer. The present role of epirubicin and doxorubicin,” *Journal of chemotherapy (Florence, Italy)*. Informa UK Limited, 5(3), pp. 207–211. doi: 10.1080/1120009x.1993.11739234.
- Pollett, J. B. *et al.* (2002) “Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance,” *Blood*. American Society of Hematology, 100(10), pp. 3819–3821. doi: 10.1182/blood-2002-02-0608.
- Pommier, Y. *et al.* (2010) “DNA topoisomerases and their poisoning by anticancer and antibacterial drugs,” *Chemistry & biology*. Elsevier BV, 17(5), pp. 421–433. doi: 10.1016/j.chembiol.2010.04.012.
- Pugazhendhi, A. *et al.* (2018) “Toxicity of Doxorubicin (Dox) to different experimental organ systems,” *Life sciences*. Elsevier BV, 200, pp. 26–30. doi: 10.1016/j.lfs.2018.03.023.
- Qiao, J.-H. *et al.* (2015) “Clinical significance of topoisomerase 2A expression and gene change in operable invasive breast cancer,” *Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine*. Springer Science and Business Media LLC, 36(9), pp. 6833–6838. doi: 10.1007/s13277-015-3390-6.
- Qin, S. *et al.* (2018) “Dowregulation of OTX1 attenuates gastric cancer cell proliferation, migration and invasion,” *Oncology reports*. Spandidos Publications. doi: 10.3892/or.2018.6596.
- Saeger, W., Schreiber, S. and Lüdecke, D. K. (2001) “Cyclins D1 and D3 and topoisomerase II $\alpha$  in inactive pituitary adenomas,” *Endocrine pathology*. Springer Science and Business Media LLC, 12(1), pp. 39–48. doi: 10.1385/ep:12:1:39.

- Saginala, K. *et al.* (2020) "Epidemiology of bladder cancer," *Medical sciences (Basel, Switzerland)*. MDPI AG, 8(1), p. 15. doi: 10.3390/medsci8010015.
- Sawazaki, H. (2021). "Expressions of P-Glycoprotein, Multidrug Resistance Protein 1 and Annexin A2 as Predictive Factors for Intravesical Recurrence of Bladder Cancer after the Initial Transurethral Resection and Immediate Single Intravesical Instillation of Adriamycin". *Asian Pac J Cancer Prev*;22(5):1459-1466. doi: 10.31557/APJCP.2021.22.5.1459. PMID: 34048174; PMCID: PMC8408374.
- Scher, H. I. *et al.* (2013) "Validation and clinical utility of prostate cancer biomarkers," *Nature reviews. Clinical oncology*. Springer Science and Business Media LLC, 10(4), pp. 225–234. doi: 10.1038/nrclinonc.2013.30.
- Shen, P.-L. *et al.* (2018) "Bladder preservation approach versus radical cystectomy for high-grade non-muscle-invasive bladder cancer: a meta-analysis of cohort studies," *World journal of surgical oncology*. Springer Science and Business Media LLC, 16(1). doi: 10.1186/s12957-018-1497-0.
- Shi, W. *et al.* (2019) "Long non-coding RNA LINC00346 promotes pancreatic cancer growth and gemcitabine resistance by sponging miR-188-3p to derepress BRD4 expression," *Journal of experimental & clinical cancer research: CR*. Springer Science and Business Media LLC, 38(1). doi: 10.1186/s13046-019-1055-9.
- Siegel, R. L., Miller, K. D. and Jemal, A. (2019) "Cancer statistics, 2019," *CA: a cancer journal for clinicians*. Wiley, 69(1), pp. 7–34. doi: 10.3322/caac.21551.
- Sikic, D. *et al.* (2021) "The prognostic value of FGFR3 expression in patients with T1 non-muscle invasive bladder cancer," *Cancer management and research*. Informa UK Limited, 13, pp. 6567–6578. doi: 10.2147/cmar.s318893.
- Song, X. *et al.* (2021) "FGFR leads to sustained activation of STAT3 to mediate resistance to EGFR-TKIs treatment," *Investigational new drugs*. Springer Science and Business Media LLC, 39(5), pp. 1201–1212. doi: 10.1007/s10637-021-01061-1.

- Soria, F., Giordano, A. and Gontero, P. (2020) “Transurethral resection of bladder tumor and the need for re-transurethral resection of bladder tumor: time to change our practice?,” *Current opinion in urology*. Ovid Technologies (Wolters Kluwer Health), 30(3), pp. 370–376. doi: 10.1097/mou.0000000000000751.
- Soukup, V. *et al.* (2017) “Prognostic performance and reproducibility of the 1973 and 2004/2016 world health organization grading classification systems in non-muscle-invasive bladder cancer: A European association of urology non-muscle invasive bladder cancer guidelines panel systematic review,” *European urology*. Elsevier BV, 72(5), pp. 801–813. doi: 10.1016/j.eururo.2017.04.015.
- Srikantan, S. *et al.* (2011) “Translational control of TOP2A influences doxorubicin efficacy,” *Molecular and cellular biology*. Informa UK Limited, 31(18), pp. 3790–3801. doi: 10.1128/MCB.05639-11.
- Strimbu, K. and Tavel, J. A. (2010) “What are biomarkers?,” *Current opinion in HIV and AIDS*. Ovid Technologies (Wolters Kluwer Health), 5(6), pp. 463–466. doi: 10.1097/coh.0b013e32833ed177.
- Sylvester, R. J., Oosterlinck, W. and van der MEIJDEN, A. P. M. (2004) “A Single Immediate Postoperative Instillation of Chemotherapy Decreases The Risk of Recurrence In Patients With Stage Ta T1 Bladder Cancer: A Meta-Analysis of Published Results of Randomized Clinical Trials,” *The journal of urology*. Ovid Technologies (Wolters Kluwer Health), 171(6 Part 1), pp. 2186–2190. doi: 10.1097/01.ju.0000125486.92260.b2.
- Szymczyk, J. *et al.* (2021) “FGF/FGFR-dependent molecular mechanisms underlying anti-cancer drug resistance,” *Cancers*. MDPI AG, 13(22), p. 5796. doi: 10.3390/cancers13225796.
- Tabayoyong, W. B. *et al.* (2018) “Systematic review on the utilization of maintenance intravesical chemotherapy in the management of non-muscle-invasive bladder cancer,” *European urology focus*. Elsevier BV, 4(4), pp. 512–521. doi: 10.1016/j.euf.2018.08.019.

- Teo, M. Y. *et al.* (2020) “Fibroblast growth factor receptor 3 alteration status is associated with differential sensitivity to platinum-based chemotherapy in locally advanced and metastatic urothelial carcinoma,” *European urology*. Elsevier BV, 78(6), pp. 907–915. doi: 10.1016/j.eururo.2020.07.018.
- Teoh, J. Y.-C. *et al.* (2022) “Recurrence mechanisms of non-muscle-invasive bladder cancer — a clinical perspective,” *Nature reviews. Urology*. Springer Science and Business Media LLC, 19(5), pp. 280–294. doi: 10.1038/s41585-022-00578-1.
- Terrinoni, A. *et al.* (2011) “OTX1 expression in breast cancer is regulated by p53,” *Oncogene*. Springer Science and Business Media LLC, 30(27), pp. 3096–3103. doi: 10.1038/onc.2011.31.
- Tomaszewski, J. J. and Smaldone, M. C. (2010) “Emerging intravesical therapies for management of nonmuscle invasive bladder cancer,” *Open access journal of urology*. Dove Medical Press Ltd., 2, pp. 67–84. doi: 10.2147/oaju.s7237.
- Tomlinson, D. C. *et al.* (2005) “Alternative splicing of Fibroblast growth factor receptor 3 produces a secreted isoform that inhibits Fibroblast growth factor–induced proliferation and is repressed in urothelial carcinoma cell lines,” *Cancer research*. American Association for Cancer Research (AACR), 65(22), pp. 10441–10449. doi: 10.1158/0008-5472.can-05-1718.
- Tu, X.-P. *et al.* (2020) “OTX1 exerts an oncogenic role and is negatively regulated by miR129-5p in laryngeal squamous cell carcinoma,” *BMC cancer*. Springer Science and Business Media LLC, 20(1). doi: 10.1186/s12885-020-07279-1.
- Umbas, R. *et al.* (2015) “Urologic cancer in Indonesia,” *Japanese journal of clinical oncology*. Oxford University Press (OUP), 45(8), pp. 708–712. doi: 10.1093/jjco/hyv066.
- Uusküla-Reimand, L. and Wilson, M. D. (2022) “Untangling the roles of TOP2A and TOP2B in transcription and cancer,” *Science advances*. American Association for the Advancement of Science (AAAS), 8(44), p. eadd4920. doi: 10.1126/sciadv.add4920.

- Vagapova, E. *et al.* (2021) "Selective inhibition of HDAC class I sensitizes leukemia and neuroblastoma cells to anticancer drugs," *Biomedicines*. MDPI AG, 9(12), p. 1846. doi: 10.3390/biomedicines9121846.
- Wang, F. *et al.* (2008) "*UCA1*, a non-protein-coding RNA up-regulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion," *FEBS letters*. Wiley, 582(13), pp. 1919–1927. doi: 10.1016/j.febslet.2008.05.012.
- Wang, K. *et al.* (2023) "EZH2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A," *Journal of experimental & clinical cancer research: CR*, 42(1), p. 320. doi: 10.1186/s13046-023-02855-2.
- Wang, L. *et al.* (2019) "Fibroblast growth factor receptor 3 alterations and response to PD-1/PD-L1 blockade in patients with metastatic urothelial cancer," *European urology*. Elsevier BV, 76(5), pp. 599–603. doi: 10.1016/j.eururo.2019.06.025.
- Wang, T.-W. *et al.* (2019) "Comparison of gemcitabine and anthracycline antibiotics in prevention of superficial bladder cancer recurrence," *BMC urology*. Springer Science and Business Media LLC, 19(1), p. 90. doi: 10.1186/s12894-019-0530-0.
- Wang, Z. *et al.* (2020) "Clinical application of drug sensitive gene detection in postoperative instillation for non-muscle invasive bladder cancer," *BMC nephrology*. Springer Science and Business Media LLC, 21(1). doi: 10.1186/s12882-020-02073-4.
- Wang, Z. *et al.* (2023) "Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy," *npj precision oncology*, 7(1), p. 70. doi: 10.1038/s41698-023-00417-5.
- Warli, S. M. *et al.* (2019) "Upregulation of FGFR3 and HIF-1 $\alpha$  expression in muscle invasive bladder cancer," *Medical Journal of Indonesia*. Faculty of Medicine, Universitas Indonesia, 28(1), pp. 3–7. doi: 10.13181/mji.v28i1.2396.

- Wéber, A. *et al.* (2024) “Global burden of bladder cancer mortality in 2020 and 2040 according to GLOBOCAN estimates,” *World journal of urology*. Springer Science and Business Media LLC, 42(1). doi: 10.1007/s00345-024-04949-8.
- Winters, B. R. *et al.* (2018) “Health related quality of life following radical cystectomy: Comparative analysis from the medicare health outcomes survey,” *The journal of urology*. Ovid Technologies (Wolters Kluwer Health), 199(3), pp. 669–675. doi: 10.1016/j.juro.2017.08.111.
- Wo, L. *et al.* (2022) “Up-regulation of LncRNA UCA1 by TGF- $\beta$  promotes doxorubicin resistance in breast cancer cells,” *Immunopharmacology and immunotoxicology*. Informa UK Limited, 44(4), pp. 492–499. doi: 10.1080/08923973.2022.2054428.
- Woldu, S. L., Bagrodia, A. and Lotan, Y. (2017) “Guideline of guidelines: non-muscle-invasive bladder cancer,” *BJU international*. Wiley, 119(3), pp. 371–380. doi: 10.1111/bju.13760.
- Xiao, J.-F. *et al.* (2021) “Targetable pathways in advanced bladder cancer: FGFR signaling,” *Cancers*. MDPI AG, 13(19), p. 4891. doi: 10.3390/cancers13194891.
- Xie, Y. *et al.* (2021) “ADNP prompts the cisplatin-resistance of bladder cancer via TGF- $\beta$ -mediated epithelial-mesenchymal transition (EMT) pathway,” *Journal of cancer*. Ivyspring International Publisher, 12(17), pp. 5114–5124. doi: 10.7150/jca.58049.
- Xu, X.-L. *et al.* (2015) “Topo2A as a prognostic biomarker for patients with resectable esophageal squamous cell carcinomas,” *Medical oncology (Northwood, London, England)*. Springer Science and Business Media LLC, 32(1). doi: 10.1007/s12032-014-0396-7.
- Xue, M. *et al.* (2016) “Long non-coding RNA urothelial cancer-associated 1 promotes bladder cancer cell migration and invasion by way of the hsa-miR-145-ZEB1/2-FSCN1 pathway,” *Cancer science*. Wiley, 107(1), pp. 18–27. doi: 10.1111/cas.12844.

- Xue, M. *et al.* (2017) “Hypoxic exosomes facilitate bladder tumor growth and development through transferring long non-coding RNA-UCA1,” *Molecular cancer*. Springer Science and Business Media LLC, 16(1). doi: 10.1186/s12943-017-0714-8.
- Yang, C.-Y. *et al.* (2020) “OTX1 is a novel regulator of proliferation, migration, invasion and apoptosis in lung adenocarcinoma,” *European review for medical and pharmacological sciences*, 24(18), pp. 9497–9510. doi: 10.26355/eurev\_202009\_23035.
- Yang, X., Xu, L. and Yang, L. (2023) “Recent advances in EZH2-based dual inhibitors in the treatment of cancers,” *European journal of medicinal chemistry*. Elsevier BV, 256(115461), p. 115461. doi: 10.1016/j.ejmech.2023.115461.
- Yao, F., Wang, Q. and Wu, Q. (2019) “The prognostic value and mechanisms of lncRNA UCA1 in human cancer,” *Cancer management and research*. Informa UK Limited, 11, pp. 7685–7696. doi: 10.2147/cmar.s200436.
- Ye, T. *et al.* (2017) “Long non-coding RNA linc00346 promotes the malignant phenotypes of bladder cancer,” *Biochemical and biophysical research communications*. Elsevier BV, 491(1), pp. 79–84. doi: 10.1016/j.bbrc.2017.07.045.
- Yeo, C. Q. X. *et al.* (2016) “P53 maintains genomic stability by preventing interference between transcription and replication,” *Cell reports*, 15(1), pp. 132–146. doi: 10.1016/j.celrep.2016.03.011.
- Yu, D.-S. *et al.* (2017) “Comparison of therapeutic efficacy of lipo-doxorubicin and doxorubicin in treating bladder cancer,” *Urological science*. Medknow, 28(4), pp. 200–205. doi: 10.1016/j.urols.2016.08.001.
- Yu, K. *et al.* (2014) “OTX1 promotes colorectal cancer progression through epithelial-mesenchymal transition,” *Biochemical and biophysical research communications*. Elsevier BV, 444(1), pp. 1–5. doi: 10.1016/j.bbrc.2013.12.125.

- Yu, S. H. *et al.* (2024) “FGFR3 mutations in urothelial carcinoma: A single-center study using next-generation sequencing,” *Journal of clinical medicine*. MDPI AG, 13(5), p. 1305. doi: 10.3390/jcm13051305.
- Yu, Z. *et al.* (2019) “DNA topoisomerase II $\alpha$  and RAD21 cohesin complex component are predicted as potential therapeutic targets in bladder cancer,” *Oncology letters*. Spandidos Publications. doi: 10.3892/ol.2019.10365.
- Yun, J. *et al.* (2019) “YH25448, an irreversible EGFR-TKI with potent intracranial activity in EGFR mutant non-small cell lung cancer,” *Clinical cancer research: an official journal of the American Association for Cancer Research*. American Association for Cancer Research (AACR), 25(8), pp. 2575–2587. doi: 10.1158/1078-0432.ccr-18-2906.
- Zeng, S. *et al.* (2019) “Prognostic value of TOP2A in bladder urothelial carcinoma and potential molecular mechanisms,” *BMC cancer*. Springer Science and Business Media LLC, 19(1). doi: 10.1186/s12885-019-5814-y.
- Zhang, Q. *et al.* (2023) “OTX1 silencing suppresses ovarian cancer progression through inhibiting the JAK/STAT signaling,” *Tissue & cell*. Elsevier BV, 82(102082), p. 102082. doi: 10.1016/j.tice.2023.102082.
- Zhang, S. *et al.* (2017) “Long non-coding RNA UCA1 promotes cell progression by acting as a competing endogenous RNA of ATF2 in prostate cancer,” *American journal of translational research*. e-Century Publishing Corporation, 9(2), pp. 366–375. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340673/> (Accessed: July 8, 2024).
- Zhao, H. *et al.* (2022) “Long non-coding RNA UCA1 promotes glutamine-driven anaplerosis of bladder cancer by interacting with hnRNP I/L to upregulate GPT2 expression,” *Translational oncology*. Elsevier BV, 17(101340), p. 101340. doi: 10.1016/j.tranon.2022.101340.
- Zhao, X. and Wu, X. (2021) “Polycomb-group proteins in the initiation and progression of cancer,” *Yi chuan xue bao [Journal of genetics and genomics]*. Elsevier BV, 48(6), pp. 433–443. doi: 10.1016/j.jgg.2021.03.013.

- Zhen, S. *et al.* (2018) “Synergistic antitumor effect on bladder cancer by rational combination of programmed cell death 1 blockade and CRISPR-Cas9-mediated long non-coding RNA urothelial carcinoma associated 1 knockout,” *Human gene therapy*. Mary Ann Liebert Inc, 29(12), pp. 1352–1363. doi: 10.1089/hum.2018.048.
- Zhou, H. *et al.* (2020) “Analysis of lncRNA UCA1-related downstream pathways and molecules of cisplatin resistance in lung adenocarcinoma,” *Journal of clinical laboratory analysis*. Wiley, 34(8), p. e23312. doi: 10.1002/jcla.23312.
- Zhou, L. *et al.* (2022) “OTX1 promotes tumorigenesis and progression of cervical cancer by regulating the Wnt signaling pathway,” *Oncology reports*. Spandidos Publications, 48(5). doi: 10.3892/or.2022.8419.
- Zou, F. *et al.* (2016) “Targeted deletion of miR-139-5p activates MAPK, NF- $\kappa$ B and STAT3 signaling and promotes intestinal inflammation and colorectal cancer,” *The FEBS journal*. Wiley, 283(8), pp. 1438–1452. doi: 10.1111/febs.13678.